Nociceptin/orphanin FQ (N/OFQ) is the endogenous peptide agonist for the N/OFQ receptor (NOP).
this receptor produces variable effects on the nociceptive (pain) response in laboratory animals, with N/OFQ and NOP agonists in general producing antinociception when given spinally and pro-nociceptive/anti-opioid actions when administered supraspinally in rodents. Spinal administration of N/OFQ or NOP agonists also produces antinociception in nonhuman primates. 1 3 The link to the clinic, as is often the case, revolves around discovery and evaluation of novel chemical entities: the pharmaceutical pipeline. The N/OFQ -NOP system is no exception in this regard. Indeed, in 2004, one of us (D.G.L.) wrote an editorial 'Nociceptin/Orphanin FQ peptide receptor system; are we any nearer the clinic?'. 4 At that time, there were some limited studies in urology examining intravesical instillation for bladder instability, 5 and a number of simple plasma measurements in patients with a range of clinical diseases. 4 We raised several issues including what is the best model/disease to study, and suggested pain. However, all work required development of small non-peptide molecules with good oral bioavailability. Researchers at Grunenthal GmbH recently reported the development and pharmacology of a novel ligand that targets NOP and other members of the opioid receptor family, in particular the MOP receptor. 6 7 This molecule, named cebranopa-
, represents a major development in opioid pharmacology for a number of reasons. In contrast to the accepted norm of designing highly selective ligands for a single target (usually MOP), cebranopadol is a non-selective ligand acting at more than one member of the opioid receptor family. There has been much interest in multi-targeting of opioids, 8 due to overlapping expression in the pain pathway, 3 including NOP, 9 but few molecules are so well characterized as cebranopadol, and there has been significant clinical development of this molecule.
Cebranopadol is both a NOP and MOP agonist, a single molecule with affinities for more than one receptor. The benefits of a non-selective drug that combines different modes of action over 'polypharmacy' or bivalent compounds (two drug structures joined by a linker molecule) are numerous. The small size of the drug facilitates entry into the central nervous system, an issue raised by the usually bulkier structure of bivalent drugs. Secondly, the pharmacokinetics (distribution, metabolism) of a single drug with different modes of action are more predictable. 8 Such compounds have demonstrated synergistic effects and lower side-effect profiles.
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Cebranopadol In vitro pharmacology
Radioligand binding to recombinant human and native rat opioid receptors shows similar nanomolar affinities for NOP and MOP with 3-to 38-fold lower affinity for KOP in the human and rat. Affinity for DOP in humans is 20-fold lower than for NOP or MOP. At recombinant human receptors, cebranopadol is a full agonist at MOP and displays 'almost full efficacy' at NOP.
Cebranopadol In vivo pharmacology
The in vivo characterization of cebranopadol is particularly thorough, and encompasses a wide range of animal painrelated paradigms along with assessment of typical opioid side-effects. In the tail-flick test in rats (a test of acute antinociception), cebranopadol was effective i.v. (time to peak effect 20 min) and p.o. (time to peak effect 90 min). In comparison with fentanyl (30 min) and morphine (3 h), the antinociceptive effect of an equi-effective dose of cebranopadol lasted 7 h. Cebranopadol is effective i.v. in a range of models of chronic pain including Freund's adjuvant-induced arthritis (nociceptive), bone cancer pain (nociceptive and neuropathic), diabetic polyneuropathy (neuropathic), and spinal nerve ligationinduced pain (nociceptive and neuropathic). In these models, half-maximal effective doses of between 0.5 and 5.6 mg kg
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were quoted; these are over 2-3 orders of magnitude more BJA Editorials potent than the gold standard morphine. Pharmacokinetic analysis in the rat shows rapid absorption and widespread distribution, with oral bioavailability of 13 -23%. Tolerance to opioids is a particularly troublesome side-effect that leads to dose escalation. Dose escalation per se leads to increased tolerance and a vicious cycle ensues. 13 There is good evidence that mixed opioids might be beneficial in this regard, with data showing morphine tolerance is reduced in DOP 14 and endogenous d-opioid peptide ppENK knockouts, 15 and by co-administration of a DOP antagonist. 16 From a clinical perspective, the non-selective opioid buprenorphine (acting as a weak partial agonist at MOP and NOP and an antagonist at KOP) displays synergistic antinociceptive effects and reduced onset, but not complete blockade, of tolerance and dependence, making it favourable in the treatment of opioid addiction. 17 In the rat, tolerance to morphine develops quickly; in this study, animals were completely tolerant to morphine (8.8 mg kg 21 i.p. daily) in 11 days. In contrast, an equi-analgesic dose of cebranopadol (only 0.8 mg kg 21 i.p. daily) was still effective for a further 15 days, or 26 days in total. For the N/OFQ-NOP system, evidence suggests that NOP antagonism reduces tolerance to morphine, 18 19 while NOP activation reduces the manifestations of drug dependence. 20 21 This is at variance with data for cebranopadol, but it should be remembered that these studies modulated NOP and MOP simultaneously with two discrete ligands. Typical opioid-induced side-effects include loss of motor co-ordination and respiratory depression. In the rotarod test for motor co-ordination, i.v. doses of cebranopadol that were analgesic were ineffective; morphine (i.v.) at analgesic doses profoundly affected motor co-ordination. Using whole-body plethysmography to assess respiratory function, i.v. doses of cebranopadol that were analgesic produced a transient increase in respiratory rate and tidal volume, while morphine (s.c.) produced a profound depression of respiration.
Cebranopadol Clinical development
Cebranopadol is currently being co-developed globally by Grü nenthal and Forest Research Institute, Inc. Excluding phase I first in man, publicly available clinical trial databases indicate that there are six completed and one ongoing phase II trials and one ongoing phase III trial in cancer pain ( Table 1) .
All of these studies appear to be based on the preclinical profile already published. The scientific and patient community eagerly await the results of these trials. 
